Ultralife (NASDAQ:ULBI - Get Free Report) issued its quarterly earnings results on Friday. The technology company reported ($0.03) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.15 by ($0.18), Zacks reports. Ultralife had a positive return on equity of 3.10% and a negative net margin of 3.09%.
Here are the key takeaways from Ultralife's conference call:
- Q1 revenue was $47.4 million with an operating loss of $0.2 million and a net loss of $0.5 million (‑$0.03/sh), attributed to shipment timing, Middle East delivery delays, plant reorganizations, weather-related interruptions, and pre‑revenue staffing and consulting costs.
- Consolidated gross margin dropped to 21.3% (down 380 bps) and gross profit fell 20.7% year‑over‑year, driven largely by lost production days (Newark substation failure and a 16‑day equivalent impact at Raynham during ERP/inventory transition), higher energy costs, and unfavorable sales mix/tariffs.
- The company exited Q1 with a record backlog of $115.1 million (up 21% YoY), representing 61% of trailing‑12‑month sales and including over $12 million of new‑product backlog, providing stronger near‑term revenue visibility.
- Management is investing in product development and vertical integration (Electrochem), expects to more than double internal cell usage, shipped the first conformal wearable battery order with > $8 million backlog, and won a $4 million multi‑year award—actions intended to stabilize Communications Systems revenue and lift gross margins.
Ultralife Stock Performance
Shares of ULBI stock traded down $1.08 during trading hours on Friday, hitting $5.97. 131,366 shares of the company were exchanged, compared to its average volume of 44,552. The firm has a fifty day simple moving average of $6.64 and a 200 day simple moving average of $6.30. The company has a current ratio of 2.83, a quick ratio of 1.39 and a debt-to-equity ratio of 0.35. Ultralife has a 52-week low of $4.78 and a 52-week high of $9.52. The stock has a market capitalization of $99.46 million, a price-to-earnings ratio of -16.58 and a beta of 0.74.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the business. Lazard Asset Management LLC boosted its holdings in Ultralife by 1,650.0% in the 2nd quarter. Lazard Asset Management LLC now owns 5,565 shares of the technology company's stock worth $49,000 after buying an additional 5,247 shares during the period. Empowered Funds LLC bought a new position in Ultralife in the 4th quarter worth approximately $44,000. Prelude Capital Management LLC bought a new position in Ultralife in the 3rd quarter worth approximately $71,000. Bank of America Corp DE boosted its holdings in Ultralife by 30.7% in the 4th quarter. Bank of America Corp DE now owns 12,067 shares of the technology company's stock worth $90,000 after buying an additional 2,836 shares during the period. Finally, Jane Street Group LLC bought a new position in Ultralife in the 4th quarter worth approximately $75,000. 30.68% of the stock is owned by institutional investors.
Ultralife Company Profile
(
Get Free Report)
Ultralife Corporation NASDAQ: ULBI develops, manufactures and sells a broad range of energy and communications products for defense, medical, automotive and consumer electronics markets. The company operates through two primary segments: Power Systems and Communications Systems. In its Power Systems segment, Ultralife produces lithium-ion rechargeable cells and battery packs, primary lithium batteries, alkaline and rechargeable battery packs, chargers and battery accessories designed to meet demanding performance and safety requirements.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Ultralife, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ultralife wasn't on the list.
While Ultralife currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here

We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.